Controls severe nausea and vomiting. ANDA 218515, held by Ajanta Pharma Ltd. Prochlorperazine Maleate.
As of Nov 16, 2026, ANDA 218515 (Prochlorperazine Maleate), held by Ajanta Pharma Ltd, was first approved by FDA on May 9, 2024, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines).
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 9, 2024 | Original application | Approved | None posted |
| Prochlorperazine MaleateEQ 5MG BASE · tablet;oral | Prochlorperazine Maleate | Rx |
| Prochlorperazine MaleateEQ 10MG BASE · tablet;oral | Prochlorperazine Maleate | Rx |
| Jan 22, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 9, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters